secwatch.observer — SEC 8-K summary
======================================

Issuer:     MACROGENICS INC (MGNX)
CIK:        0001125345
Form:       8-K
Filed at:   2022-10-17T23:59:59+00:00
Accession:  0001125345-22-000092
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MacroGenics and Gilead sign $60M upfront option deal for MGD024 and two bispecific programs
--------------------------------------------------------------------------------

- Upfront $60M from Gilead; potential milestones up to $1.7B for MGD024 and two research programs.
- Gilead gets exclusive option to license MGD024 (Phase 1 CD123×CD3 DART) for AML and MDS.
- MacroGenics to continue Phase 1 study; Gilead may exercise option at predefined decision points.
- Tiered double-digit royalties on MGD024 net sales; flat royalties on products from two research programs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1125345/000112534522000092/0001125345-22-000092-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1125345/000112534522000092/mgnx-20221017.htm
  HTML page:      https://secwatch.observer/filing/0001125345-22-000092

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer